Table 8.
Anti-fracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomised controlled trials (updated from [3])
| Effect on vertebral fracture risk | Effect on non-vertebral fracture risk | |||
|---|---|---|---|---|
| Osteoporosis | Established osteoporosisa | Osteoporosis | Established osteoporosisa | |
| Alendronate | + | + | NA | + (including hip) |
| Risedronate | + | + | NA | + (including hip) |
| Ibandronate | NA | + | NA | + b |
| Zoledronic acid | + | + | NA | + c |
| HRT | + | + | + | + (including hip) |
| Raloxifene | + | + | NA | NA |
| Teriparatide | NA | + | NA | + |
| Denosumab | + | + c | + (including hip) | + c |
NA no evidence available, + effective drug
aWomen with a prior vertebral fracture
bIn subsets of patients only (post hoc analysis)
cMixed group of patients with or without prevalent vertebral fractures